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A B S T R A C T
Late stage breast cancer commonly metastasises to bone and patient survival averages 2–3 years following
diagnosis of bone involvement. One of the most successful treatments for bone metastases is the bisphosphonate,
zoledronic acid (ZOL). ZOL has been used in the advanced setting for many years where it has been shown to
reduce skeletal complications associated with bone metastasis. More recently, several large adjuvant clinical
trials have demonstrated that administration of ZOL can prevent recurrence and improve survival when given in
early breast cancer. However, these promising effects were only observed in post-menopausal women with
confirmed low concentrations of circulating ovarian hormones. In this review we focus on potential interactions
between the ovarian hormone, oestrogen, and ZOL to establish credible hypotheses that could explain why anti-
tumour effects are specific to post-menopausal women. Specifically, we discuss the molecular and immune cell
driven mechanisms by which ZOL and oestrogen affect the tumour microenvironment to inhibit/induce tumour
growth and how oestrogen can interact with zoledronic acid to inhibit its anti-tumour actions.
1. Introduction
Late stage breast cancer commonly metastasises to bone, lung, liver
and brain with bone being the predominant site. There are currently no
curative treatments for metastatic breast cancer and patient survival
averages 2–3 years following initial diagnosis of bone involvement [1].
One of the most successful bisphosphonates for the treatment of bone
metastases is zoledronic acid (ZOL). This drug has several roles in
breast cancer management not just in the advanced metastatic setting
but also in the early curative setting. In the advanced setting, ZOL has
been shown to reduce the skeletal complications associated with bone
metastases. In the early setting, ZOL prevents the bone loss that is as-
sociated with curative systemic cancer therapies, reducing bone loss
and fracture rates in post-menopausal women, and the high level of
treatment-induced bone loss in premenopausal women.
More recently, the efficacy of bisphosphonates to prevent breast
cancer recurrence and improve survival, when given in early breast
cancer, has been evaluated in large adjuvant breast cancer trials. These
trials have demonstrated promising results for post-menopausal women
(natural or biochemical) showing that these drugs are effective at
preventing recurrence, however, the same treatment results in worse
outcome and increased recurrence in pre-menopausal women [2–6].
During the menopause there are dramatic shifts in circulating con-
centrations of steroid hormones with reduced oestrogen, inhibin and
concomitant increases in follicle stimulating hormone (FSH) [7]. Evi-
dence from clinical and pre-clinical studies indicate that, in an adjuvant
setting, the anti-tumour efficacy of ZOL correlates specifically with
circulating concentrations of oestrogen, we therefore hypothesise that
oestrogen can inhibit anti-tumour effects of this bisphosphonate. In this
review we focus on clinical evidence that oestrogen is the key hormone
that influences the anti-tumour effects of ZOL and the pre-clinical evi-
dence describing the physiological mechanisms driving this phenom-
enon. Specifically, we discuss the molecular and immune cell driven
mechanisms by which ZOL and oestrogen affect the tumour micro-
environment to inhibit/induce tumour growth and how oestrogen can
interact with zoledronic acid to inhibit its anti-tumour actions.
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2. Evidence from clinical studies
2.1. Incidence/prevalence of bone metastasis after early breast cancer
according to menopausal status
Bone is the most common site of metastasis in advanced breast
cancer with almost 70% of metastatic patients experiencing bone in-
volvement [8]. Although, these patients have considerably increased
morbidity and decreased survival and quality of life, a recent study
showed that women with only bone metastases have better survival
compared to women with visceral metastases [9]. This study included
7064 women with breast cancer who were diagnosed between 1975
and 2006 at Guy’s Hospital in London, UK and were followed up for
disease recurrence patterns until the end of 2010. Results showed that
the incidence of bone metastases was higher in women younger than
40-year-old compared to the rest of the age groups (29.6%<40-year-
old, 23% 40–49-year-old, 25.1% 50–59-year-old, 21.7% 60–69-year-old
and 15.3%>70-year-old) and significantly higher in women who were
diagnosed with breast cancer before the age of 40 compared with those
who were diagnosed when over 70. Earlier data from Braun et al., in
which they evaluated data from 9 different studies (n = 4703 patients
in total) assessed the importance of micro-metastasis in bone marrow
aspirates at the time of early breast cancer diagnosis of women with
stage I, II and III disease [10]. The study indicated that the incidence of
bone marrow disseminated tumour cells (DTC) was higher in pre-
menopausal women and that the bone marrow of these women may be
more attractive to tumour cells than the bone marrow of post-meno-
pausal women (32.7% and 29.5% respectively; P = 0.02). Furthermore,
a greater significance was seen when comparing age with disseminated
tumour cells in bone. Tumour cells were detected in the bones of 34.5%
of 20–35 year olds compared with 27.8% of women over 65
(P = 0.001). Taken together, these data imply that the longer a woman
has been post-menopausal the less attractive the bone microenviron-
ment may be for tumour cells [10].
2.2. Use of zoledronic acid to treat disseminated tumour cells (DTCs) in
bone according to menopausal status
Breast cancer patients can experience recurrence of their disease
many years after the removal of the primary breast cancer. This is due
to the long-term survival of DTCs which stay dormant for years before
they are stimulated to proliferate into overt metastases. Studies showed
that 30–40% of breast cancer patients have DTCs in their bone marrow
and the presence of these are an adverse prognostic risk factor for
distant metastasis and mortality [10]. DTCs have been detected fol-
lowing cytotoxic chemotherapy treatments, demonstrating their ability
to resist conventional treatments and their persistence post che-
motherapy is strongly associated with poor outcomes [11 12]. There-
fore, multiple clinical studies have evaluated the effects of alternative
treatments and more specifically the effects of bone targeted agents,
bisphosphonates, on DTC survival in bone, with promising results.
In a non-randomised phase 2 trial, 31 women (36.9% pre-meno-
pausal/63.1% post-menopausal) with early breast cancer and persistent
DTCs in their bone marrow, received 4 mg of ZOL 4 weekly for
6 months, after the completion of their adjuvant treatment compared
with 141 controls (41.9% pre-menopausal/58.1% post-menopausal)
[13]. Follow up bone marrow aspirations showed elimination of DTCs
in 87% of ZOL treated patients compared to 73% of controls, but the
reduction in the total number of DTCs between the first (pre ZOL) and
the second (6 months post ZOL) bone marrow aspirate was statistically
significant only in ZOL group (p = 0.02 vs p = 0.14). The elimination
of DTCs in control group was thought to be due to immune related
clearance as well as the anticancer systemic and endocrine treatment
that patients received. Also, negative aspirations were associated with
better survival. In 2013, in a randomised controlled open-label multi-
centre study, 86 women with DTC-positive bone marrow were
randomised to receive standard adjuvant systemic treatment with or
without ZOL every 4 weeks for 24 months (35% pre-menopausal/65%
post-menopausal and 37% pre-menopausal/63% post-menopausal re-
spectively) [14]. After the completion of the ZOL treatment, all treated
patients (n = 40) had negative bone marrow results compared to 16%
of controls who had persistent DTCs in their bone marrow (n = 46).
Effects of ZOL were also assessed in combination with neoadjuvant
treatment in a phase-2 randomised single centre study [15] Women
with early breast cancer were allocated to receive ZOL 4 mg every
3 weeks (n = 60) or no ZOL (n = 60), for 12 months, along with 4
cycles of neoadjuvant epirubicin plus docetaxel and 2 cycles of adjuvant
epirubicin and docetaxel. After 3 months of treatment, the number of
patients with detectable DTCs reduced more in the ZOL group com-
pared to the chemotherapy only group. Also, it was more likely for the
ZOL treated patients to remain DTC negative after this period of time.
However, at 12 months, there was no difference in the number of DTC-
positive patients between the two groups most likely due to the small
number of patients or the different adjuvant treatments that patients
received after the first 3 months. The largest study which investigated
the impact of ZOL on DTCs, was published in 2014 [16]. 3141 patients
with early breast cancer underwent bone marrow aspirates and 803 of
them had detectable DTCs. Both DTC-positive and negative patients
received systemic treatment and adjuvant ZOL based on national
guidelines (bisphosphonates were also offered in the context of 3 clin-
ical studies, GAIN, NATAN and SUCCESS A). Retrospective analysis
showed that bisphosphonates were associated with better DFS (disease
free survival) and OS (overall survival) in DTC-positive participants.
Although, all of the studies that have been discussed here have included
both pre- and post-menopausal women, Hartkopf et al. was the only one
that performed subgroup analysis in order to identify the effects of
bisphosphonates on DTCs based on the menopausal status. Post ad-
juvant bisphosphonate treatment, DFS was found to be better in both
pre- and post-menopausal women with detectable DTCs (p = 0.018 and
p = 0.014 retrospectively), in contrast with OS which was better only
in post-menopausal women with detectable DTCs (p = 0.009). How-
ever, these results should be interpreted with caution due to the ret-
rospective nature of the study also due to the fact that patients who
received bisphosphonates were mostly post-menopausal with detect-
able DTCs [16].
Despite the fact that clinical studies have illustrated the benefits of
ZOL on elimination of DTCs from bone marrow of women with early
breast cancer, more trials are needed in order to confirm its clinical
benefits in pre-menopausal patients. Additionally, available studies
have either had a small number of participants or not been randomised
which makes interpretation of their outcomes more difficult and the
need for further trials more crucial.
2.3. Use of bisphosphonates to prevent disease recurrence and improve
survival according to menopausal status
Adjuvant systemic treatment is offered to patients with early breast
cancer with the aim to eradicate any micrometastases present at the
time of diagnosis. Adjuvant bisphosphonates are now part of most
standard adjuvant anticancer treatment assisting the elimination of
micrometastases and increasing the chances of cure in post-menopausal
women following the results of large phase 3 trials and a patient data
meta-analysis.
The clinical benefit from the inclusion of bisphosphonates in ad-
juvant treatment was first described by GAIN, the Danish collaborative
study, ABCSG-12 and the AZURE trial [2,4,17,18]. These trials reported
improvement in disease free survival (DFS) with adjuvant bispho-
sphonates in women with low levels of systemic female hormones
(oestrogen and inhibin A) at the start of the adjuvant breast cancer
treatment.
In ABCSG-12, 1803 pre-menopausal women received adjuvant go-
serelin with endocrine treatment (tamoxifen or anastrozole), with or
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without ZOL (4 mg every 6 months for 3 years) and after 94.4 months of
medial follow up, relative risks of disease recurrence was reduced in the
ZOL arm [6]. When the data form the AZURE, trial was published (3360
women randomised to receive standard adjuvant systemic treatment
with or without ZOL (4 mg every 3–4 weeks for six doses, then every
3 months for eight doses, followed by every 6 months for five doses, for
a total period of 5 years), the overall results showed that DFS and OS
were similar in both ZOL and control group. However, women who
were 5 years into menopause appeared to benefit, with IDFS (invasive
disease free survival) of 78.2% in the ZOL arm compared to 71% in the
control arm, and OS at 5-year of 84.6% and 78.7% in ZOL and the
control group, respectively [3]. ZO-FAST, another large study, which
was designed to assess ZOL as a bone protector in post-menopausal
patients on adjuvant aromatase inhibitors (AIs) for early breast cancer,
also reported less disease recurrences in the ZOL group (4 mg 6 monthly
for 5 years) [19].
In 2015, the early Breast Cancer Trial Collaborative Group
(EBCTCG) published a meta-analysis of 26 randomised trials of ad-
juvant bisphosphonates in early breast cancer which included data from
18,766 women (EBCTCG, 2015) [20]. In the combined, meta-analysis,
the most apparent effect of bisphosphonates was in bone recurrence,
irrespective of menopausal status. However, subgroup analysis revealed
a clear benefit in post-menopausal women with decreased overall re-
currence (RR 0·86, 95% CI 0·78–0·94; 2p = 0·002), distant recurrence
(RR 0·82, 0·74–0·92; 2p = 0·0003) and mortality (RR 0·82, 0·73–0·93;
2p = 0·002).
In pre-menopausal patients, data from AZURE and ABCSG-12 and
the subsequent meta-analysis suggested benefit from adjuvant bispho-
sphonates in those patients who were on ovarian suppression therapy at
the start of their bisphosphonate treatment. In contrast, pre-meno-
pausal women rendered post-menopausal due to chemotherapy did not
have the same benefit from bisphosphonates. This suggests that me-
nopausal status at the initiation of adjuvant bisphosphonates is im-
portant. It has also been hypothesised that early interaction between
bisphosphonates and endocrine/paracrine factors in the bone micro-
environment may impact the survival of DTCs in the bone marrow
microenvironment [21].
2.4. Can ZOL influence tumour cells outside bone according to menopausal
status?
Neo-adjuvant systemic chemotherapy, given to women with early
breast cancer prior to their breast cancer surgery aims to downsize the
primary breast tumour to make women who are inoperable operable
and/or avoid of mastectomy. This treatment strategy also enables
sensitivity to systemic treatment to be assessed and pathological com-
plete response (pCR) following neo-adjuvant chemotherapy is asso-
ciated with better long-term outcomes [22].
The use of ZOL as part of the neo-adjuvant chemotherapy and its
effects on response were summarised in a meta-analysis of four ran-
domised neo-adjuvant trials [23]. Pathological complete response in
the breast tumour (pCRb) and proximal lymph nodes (pCR) of women
with stage II/III early breast cancer, were assessed in 735 and 552
women, respectively treated with ZOL compared to control. Outcome
from the overall population analysis did not show any benefit in pCRb
or pCR from the inclusion of ZOL in the neo-adjuvant systemic treat-
ment, however, in the subgroup analysis according to menopausal
status, post-menopausal women tended to have better pCRb (10.8%
versus 17.7%, OR 2.14, 95% CI 1.01–4.55, p = 0.048) and pCR (7.8%
versus 14.6%, OR –2.62, 95% CI 0.90–7.62, p = 0.076) with ZOL.
However, the data was not robust or sufficient enough in order to
change the standard of care in the neo-adjuvant setting. Further re-
search with longer follow ups and larger samples is necessary to provide
a clearer picture of the role of ZOL in influencing pCR rates dependent
upon menopausal status.
2.5. Influence of bisphosphonates on established metastatic disease in bone
according to menopausal status
In advanced breast cancer with bone metastasis, bisphosphonates
have been shown to reduce the risk for skeletal related events (SREs)
and also to prolong the onset of SREs, when they were combined with
standard anticancer treatment [24]. In two large meta-analyses
(n = 2189, n = 2806), bisphosphonate treated breast cancer women
with bone metastases had lower risk of developing SREs (17% and 15%
respectively), in comparison to placebo treated group [25,26]. The
majority of clinical studies have focused on the use of ZOL in the me-
tastatic setting with a Japanese study (n = 228) demonstrating 39%
reduction in SREs with ZOL in contrast to placebo [27]. In all the
published studies, ZOL and bisphosphonates in general, were used in
pre- and post-menopausal, and their ability to prevent SREs in meta-
static breast cancer does not seem to be affected by the menopausal
status.
3. Evidence from pre-clinical studies
3.1. Effects of zoledronic acid on tumour growth in the bone
microenvironment under pre- and post-menopausal conditions.
Tumour cells are thought to home to specific metastatic niche(s)
within the bone; the endosteal niche (made up of osteoblasts and
haematopoietic stem cells) and the peri-vascular niche [28–31]. Once
disseminated in these niches’ tumour cells are held in a dormant state
until either physiological/biological stimulus cause expansion of the
niche or dysregulation in immune response which enables outgrowth of
these disseminated tumour cells into overt metastasis. Once tumours
start to proliferate in bone they release growth factors that stimulate
maturation of osteoclasts leading to osteoclastic bone resorption, in
turn the resorbed bone releases tumour stimulating growth factors that
further stimulate tumour growth, a process commonly known as the
vicious cycle (reviewed in [32]). ZOL is a potent third generation bi-
sphosphonate with high affinity to bone. Its primary mechanism of
action is to prevent osteoclast maturation and cause osteoclast apop-
tosis via inhibition of the mevalonate pathway, thereby inhibiting
progression of the vicious cycle [33]. Because of the strong feedback
mechanism that exists between osteoclasts (required for resorption) and
osteoblasts (required for bone generation) reducing osteoclast activity
with ZOL also results in reduced osteoblast activity thereby inhibiting
expansion of the endosteal niche and tumour growth in this site (Fig. 1).
Furthermore, through inhibition of the mevalonate pathway in en-
dothelial cells, ZOL inhibits sprouting of new blood vessels preventing
expansion of the peri-vascular niche [34]. Despite these anti-cancer
properties in bone, evidence from preclinical models have demon-
strated that ZOL is only able to exert optimal anti-tumour effects under
low circulating concentrations of ovarian hormones including oes-
trogen. In mouse model systems, ovariectomy (OVX) induced meno-
pause increased bone resorption and triggerd the growth of dis-
seminated, MDA-MB-231, breast cancer cells in bone. Administration of
ZOL prevented OVX induced increases in bone resorption and growth of
disseminated cancer cells into the bone but had no effect on tumour
growth in the bones of pre-menopausal (sham operated) mice [35].
These results support the findings observed in the AZURE, ABCSG-12,
and ZO-FAST clinical trials where adding ZOL to standard of care
therapy only benefitted women with established menopause and thus
low circulating ovarian hormones [36].
Initially, the mechanism for the differential anti-tumour effects of
ZOL under pre- and post- menopausal conditions was proposed to be
mediated by altered osteoclast activity driven by menopause related
hormones [35]. Deprivation of key ovarian hormones (including oes-
trogens) following OVX results in a concomitant increase in Receptor
activator of nuclear factor kappa-Β (RANK) ligand (RANKL) in the bone
microenvironment and subsequent stimulation of osteoclast activity
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[37,38]. The RANK-RANKL pathway is essential for osteoclast ma-
turation, activation and lifespan maintenance, and disruption of this
pathway was shown to disrupt osteoclastic bone resorption and prevent
outgrowth of disseminated tumour cells in the bones of OVX mice [39],
highlighting the importance of osteoclasts in bone metastasis. However,
data obtained from in the clinic has led to the hypothesis that other cell
types may be equally or more important than osteoclasts in driving
tumour growth in bone; In the ABCGS-18 trial in which all patients
were post-menopausal administration of 60 mg of the RANKL specific
antibody, Denosumab, every 6-months reduced disease recurrence
[40]. But in the larger, D-Carestudy where the dose of denosumab was
increased to 120 mg and administration was more frequent no reduc-
tions in disease recurrence were observed irrespective of the patients
menopausal status [41]. These data suggest that reduction but not re-
moval of osteoclast activity is beneficial to prevent bone metastases
[42]. Indeed, there are a large number of bone marrow cell types, in-
cluding those of osteoclastic linages that express oestrogen receptors
and have been shown to also promote a resorptive phenotype under low
oestrogen conditions [43]. In addition, low oestrogen is associated with
an increase of inflammatory molecules in the bone microenvironment
such as interleukin (IL) -1, IL-6, and Tumour Necrosis Factor-alpha
(TNF-α), which have a direct effect on osteoclast activity [44]. There-
fore, the effect of ZOL in the bone microenvironment might depend on a
number of different factors associated with oestrogen and the meno-
pausal status, not just the actions on the osteoclast activity.
3.2. Effects of ZOL in bone microenvironment
Due to its high resemblance to a pyrophosphate molecule, ZOL
binds strongly to areas of new remodelling where the hydroxyapatite is
exposed. Although serum concentrations of ZOL decrease rapidly over a
period of few hours, its presence in bone can last several years [45].
Once ZOL is bound to the hydroxyapatite, it gets released during the
remodelling process by active osteoclasts. Uptake of ZOL by the os-
teoclast leads to inhibition of farnesyl diphosphate synthase, a critical
enzyme in the mevalonate pathway, preventing post-translational pre-
nylation of GTPases such as RAP and RAS resulting in apoptosis of the
osteoclast via caspase 3 activation [45].
In the bone environment, ZOL has modulatory effects beyond those
observed in osteoclasts, including reducing the vascular niche, in-
hibiting maturation of bone cell progenitors and killing mature cells.
The bone is a highly vascularised tissue in which the vascular niche is
closely linked with bone maintenance and tumour cell dormancy/out-
growth. ZOL has been shown to decrease the number of human vascular
endothelial cells, in vitro, in a dose dependent manner through in-
creased cellular apoptosis [34]. In addition, ZOL reduces vascular en-
dothelial cell activity and migration and changes in the morphology of
this cell type [34]. Although the mechanisms of how ZOL induced these
changes were not investigated, it is likely that the mevalonate pathway
was the main target of this drug on the vascular endothelial cells. These
findings, however, were not recapitulated in in vivomodels where blood
vessels are only exposed to ZOL for short periods of time as would be
the case in breast cancer patients [46]. When looking at the vasculature
and surrounding perivascular cell populations in BALB/c nude mice
mature mice (mimicking a pre-menopausal situation) no significant
differences in the number of vessels of ZOL treated and untreated ani-
mals were observed. Although in vitro and in vivo results contrast each
other, the in vivo study focused solely on osteoprogenitor-related vessels
(type-H) and activity and viability of these vessels were not assessed
[47]. A similar study performed in younger (4-week old) im-
munocompetent mice (mimicking a low oestrogen environment)
showed increased numbers of vessels following treatment with ZOL
[48] no alteration in activity were observed. However, in adult mice (4-
month old; mimicking pre-menopausal conditions) no significant dif-
ferences in blood vessels were observed between the ZOL treated and
control groups. Taken together, these results suggest that ZOL does not
Fig. 1. Effects of Zoledronic acid on the bone meta-
static niche and the “vicious cycle of bone metas-
tases”. Breast cancer cells arrive in the haemato-
poietic stem cell and peri-vascular niches in bone.
Stimulation of these niches promotes metastatic
outgrowth of tumour cells which emit growth factors
stimulating activity of osteoclasts and osteoblasts. In
turn, bone resorption leads to the release of bone
bound growth factors into the local microenviron-
ment that further stimulate tumour growth and ex-
pansion of the metastatic niches. ZOL interrupts this
process, directly inhibiting expansion of the meta-
static niches and impeding activity of osteoclasts
through inhibition of the mevalonate pathway. Blue
arrows indicate pro metastatic processes, red bars
indicate metastatic inhibition by ZOL. (For inter-
pretation of the references to colour in this figure
legend, the reader is referred to the web version of
this article.)
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alter the functionality or number of vessels in mature, pre-menopausal
mice (after 12-week old), however, ZOL has an increased effect in
young mice (4 and 6-week old) which may be in correlation with the
high level of development of the mouse skeletal tissue during this
period and or associated with low circulating concentrations of oes-
trogen in pre-pubescent animals. In patients populations, ZOL has been
reported to reduce the serum concentrations of VEGF, therefore, a trend
towards a decrease number of blood vessels would be expected [49],
however, no studies have been carried on human tissues to further
confirm whether ZOL increases or has no effect on the bone vasculature
or if this bisphosphonate has different effects in pre- and post-meno-
pausal women.
ZOL also directly affects haematopoietic and mesenchymal niches in
the bone microenvironment. Using an immunocompetent mouse model,
Soki et al., demonstrated that Haematopoietic stem cells are sig-
nificantly increased in number after a treatment with ZOL but their
mobility and re-localisation patterns remain unaltered [48]. It was
previously assumed that the haematopoietic niches where highly de-
pendent on osteoclasts cells for the niche mobilization to the periphery
from the bone marrow cavities. This mechanism was based on the
formation of the bone marrow cavity by an active osteoclast, therefore,
after exposure to ZOL and subsequent impaired osteoclastic activity, it
would be hypothesised that mobility of the haematopoietic niche would
be reduced [50,51]. However, these results indicate that mobilization
may not be dependent on osteoclast activity but rather an alternative
mechanism to be determined. In contrast, it is the mesenchymal niche
where a decrease in the number of osteoprogenitors (Osteoblast-specific
transcription factor Osterix (Osx) positive) and an increment in earlier,
less committed, osteoprogenitors is observed following administration
of ZOL [46]. There is substantial data showing that ZOL reduces os-
teoblast activity, overall numbers of osteoblasts in bone and genes as-
sociated with osteoblast formation [35,52]. However, this is likely to be
an oversimplification and it appears that under the selective pressure of
ZOL the osteoblasts that remain in bone re-locate to areas in bone
where they are most needed. In mouse models, the numbers of osteo-
blasts significantly increased after a single dose of ZOL but only in re-
gions of intense bone remodelling, commonly the metaphysis in long
bones (tibia and femur). Whereas in regions of low rates of bone re-
modelling, such as cortical bone or low trabecular (for tibia), the
number of osteoblasts is significantly decreased [46,53]. All of this
evidence point to ZOL having dramatic effects on the bone micro-
environment, inhibiting bone resorption and limiting expansion of the
bone metastatic niches, these are processes thought to be responsible
for reducing the ability of tumour cells to colonise and grow in bone. It
has been postulated that oestrogen may inhibit ZOL from exerting these
anti-tumour effects through its own bone anabolic actions.
3.3. Effects of low oestrogen in the bone microenvironment
Oestrogens are a group of steroidal hormones of which the most
abundant in women and rodents is oestrogen. Oestrogens play key roles
in the development and maintenance of the skeletal tissue [43]. Oes-
trogen acts through the dimerization of two different types of receptors,
oestrogen receptor-alpha (ERα) or -beta (ERβ). These receptors are
widely expressed in a great number of cell types within the bone mi-
croenvironment and their function depends on the type of receptor
activation, the level of ER expressed by the cell, the cell type, and/or
the nature of ER-dependent promoter regulatory sequences [43]. For
instance, physiological concentrations of oestrogens extend the lifespan
of osteoblasts mainly by activation of ERβ, whereas they will decrease
osteoclast lifespan via activation of ERα [54–56]. However, the me-
chanisms by which low concentrations of oestrogen affect cells within
the bone microenvironment either directly or indirectly remain to be
elucidated.
Bone cells are derived from two different cell linages; osteoblasts are
derived from a mesenchymal linage whereas osteoclasts proceed from
myeloid haematopoietic cells. Both lineages have been reported to ex-
press ER and are affected directly or indirectly by circulating oestrogen
hormones. Early osteoblastic progenitors have been shown to alter their
self-renewal mechanisms in presence of oestrogen. In physiological le-
vels of oestrogen, osteoblast progenitors are prevented from pro-
liferating and undergoing self-renewal processes, potentially by direct
activation of ERα, allowing them to commit into differentiation
[57,58]. Moreover, oestrogen increases the transcriptional levels of
adhesion molecules such as N-cadherin. These findings demonstrate
that under pre-menopausal concentrations of oestrogen, once osteo-
progenitors differentiate into osteoblast, they increase mobility mole-
cules to favour their migration to areas where resorption is taking place,
however, the loss of oestrogen impairs this ability. Osteoblast pro-
genitors respond differently to oestrogen stimulus compared with ma-
ture osteoblasts. Osteoblastic progenitors expressing Osteoblast-specific
transcription factor Osterix 1 (Osx1) (expressed in early osteoblast
differentiation) require activation of Wnt/β-catenin via ERα in order to
differentiate into functional periosteal cells and achieve optimal cor-
tical bone accrual. In contrast, mature osteoblast and osteocytes do not
respond to this stimulus [59], instead they are prevented from under-
going apoptosis by inhibiting activation of caspase-3/7 [54].
The effect of oestrogen on osteoclasts lineages is still a matter of
debate, however, evidence suggests that oestrogen affects maturation,
activation and life span of osteoclasts through direct and indirect me-
chanisms. For example, numbers of osteoclasts and osteoclast pro-
genitors are significantly increased in a mouse model knockout for ERα
in monocytes/macrophages, compared to wildtype mice, but only in the
cancellous site of the bone [56]. This study demonstrated that removal
of oestrogen signalling in the osteoclast lineage only affects the popu-
lation of osteoclast and osteoclast progenitors located in the cancellous
area of the bone decreased their lifespan. [56]. In addition, osteoclas-
togenic factors such as IL-1, IL-6, TNFα, and macrophage colony-sti-
mulating factor (M-CSF) are secreted by diverse haematopoietic and
osteoblastic cells. The production of these factors is well documented to
be dependant of oestrogen concentrations, with high concentrations of
this hormone repressing osteoclastigenesis and bone resorption [44]. In
contrast, under post-menopausal concentrations of oestrogen, increased
production of IL-1 is observed which leads to an increased differentia-
tion of osteoclastic progenitors as well as the production of RANKL by
immune cells, primarily T-cells, and osteoblastic cells resulting in
augmented numbers of active osteoclasts [44,60]. Oestrogen also plays
an additional antiresorptive role in by directly inducing apoptosis in
active osteoclasts via transforming growth factor-β1 (TGF-β) in a dose-
dependent manner [55]. Although this mechanism was observed in
osteoclast colonies in vitro, mouse model studies suggest that this me-
chanism is specificity important in the regulation of osteoclasts in the
trabecular area of the bone [56]. Importantly, data suggest that oes-
trogen has dramatic effects on a wide variety of cell types with known
links to driving tumour growth in bone including osteoblasts, haema-
topoietic stem cells and osteoclasts. Interestingly, the most striking
oestrogen driven effects on bone resorption were observed in the tra-
becular region of bone where ZOL has its most potent anti-resorptive
effects [54].
Taken together ZOL and oestrogen both have effects in bone that
preserve bone, but these are trough different mechanisms. ZOL inhibits
bone resorption through active killing of osteoclasts which has the
knock-on effect of reducing osteoblast activity, whereas, oestrogen has
bone anabolic effects through increasing the lifespan of osteoblasts and
decreasing the lifespan of osteoclasts (but increasing osteoclast pre-
cursors, therefore increasing the turnover of osteoclasts in bone). It is
therefore possible that ZOL may not be as effective at reducing bone
resorption and the vicious cycle of bone metastases because of the in-
creased numbers of osteoclasts generated. When ZOL kills the existing
osteoclasts under high concentrations of oestrogen, these may be re-
placed at a sufficiently high rate to allow continued bone resorption.
Although this simple, suggested, mechanism may partly explain the
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reduced anti-tumour effects observed following adjuvant administra-
tion of ZOL in pre-menopausal women, the most striking effects were
observed outside of bone with pre-and post-menopausal women ex-
periencing opposite outcomes; increased and decreased relapse re-
spectively [2,61]. It is therefore likely that systemic effects of oestrogen
and ZOL are responsible for these differences and both of these sub-
stances have profound effects on the immune system.
3.4. Immune landscape of breast cancer
The innate and adaptive immune systems have profound effects on
breast cancer progression and metastasis. Genetic and epigenetic
modifications in cancer results in changes in cell surface proteins
leading to expression of cancer associated antigens that can be re-
cognised by complement proteins of the immune system [62,63].
Therefore, tumour cells must evade immune recognition in order to
survive. Breast cancer cells employ immune modulatory techniques,
such as up-regulation of PD-L1, subsequent stimulation of the im-
munosuppressive regulatory T (Treg) cell populations and the polar-
isation of macrophage populations into pro-tumour subtypes. Indeed, a
study into natural killer (NK) cell activity in NK cells isolated from
breast cancer patients found that activity dropped from 62.5% to 24.4%
in patients with breast cancer when compared to healthy individuals
[64]. The presence of specific immune cell subsets within the tumour
microenvironment indicate a positive or negative survival benefit. Eo-
sinophils, neutrophils, B lymphocytes and CD4+ or CD8+ T cell in-
filtration are associated with a good prognosis. Whereas, tumour as-
sociated macrophages (TAMs), T regulatory cells (Tregs) and activated
mast cells are correlated with a poor prognosis. Both oestrogen and Zol
have profound immune modulatory effects with the potential to alter
survival of breast cancer and we suggest that immune modulation in-
stigated by high circulating concentrations of oestrogen (observed in
pre-menopausal women) may antagonise the anti-tumour immune re-
sponse stimulated by ZOL.
3.5. Effects of ZOL on anti-cancer immunity
In addition to its effects on bone cells, ZOL has profound effects on
the immune system, including a plethora of immune cell subsets ex-
pressing the mevalonate pathway enzymes, leading to a general in-
crease in anti-tumour immunity [65]. Specifically, ZOL can influence
macrophage polarisation in the tumour microenvironment, γδ T cell
activation by accumulation of its activating antigen on target cells, NK
cell activity, Treg cell activation and infiltration, PD-L1 expression and
effector T cell function. Therefore, understanding the interactions of
ZOL with these immune cell subsets in breast cancer metastasis could
help shed light on the mechanisms whereby adjuvant ZOL prevents
metastasis in post-menopausal women.
3.5.1. Gamma delta T cells
γδ T cells are a subset of immune-surveillance cells that detect self-
prenyl pyrophosphate metabolites to enable immune response to mi-
crobes and tumours. The majority of these cells have the Vγ9Vδ2 T cell
receptor and they are not restricted by dependence on MHC class pro-
teins, but instead require butyrophilin 3A1 from the immunoglobulin
family which is expressed on all human cells [66]. This effectively al-
lows any healthy human or tumour cell to present antigens, without the
need for MHC proteins which are often downregulated on breast cancer
cells. γδ T cells respond to the eukaryote isopentenyl pyrophosphate
(IPP), which is produced through the mevalonate pathway, and can
often accumulate in unregulated tumour cells.
ZOL inhibits the activity of farnesyl pyrophosphatase, a down-
stream enzyme of IPP in the mevalonate pathway, leading to accumu-
lation of IPP and activation of γδ T cells and subsequent tumour cell
apoptosis [67]. In In vitro studies, administration of ZOL to peripheral
blood mononuclear cells resulted in a significant expansion of the γδ T
cell subset [68]. Interestingly, ZOL has been reported to accumulate IPP
in circulating monocytes, leading to activation of circulating γδ T cells
resulting in a greater immunostimulatory effect by increasing tumour
targeting via γδ T cell degranulation and the release of cytotoxic
granules [69]. However, these peripherally activated γδ T cells lacked
the ability to migrate to tumours [70], suggesting the direct activation
of γδ T cells in the tumours by tumour cell derived IPP is necessary to
exert anti-tumour activity.
γδ T cells express PD-1 as a mechanism to differentiate between self
and non-self, in vitro experiments in the laboratory have demonstrated
that when in contact with tumour cells γδ T upregulate PD-1 making
their interactions with PD-L1 more frequent, increasing T cell exhaus-
tion and reducing their potential cytotoxicity [71]. γδ T cells isolated
from tumour bearing mice and stimulated with mitogen respond poorly
compared with those isolated from healthy mice which proliferate
readily. This inhibited proliferation was rescued by treatment with a
monoclonal antibody against PD-L1. Furthermore, ZOL has been shown
to rescue PD-L1 inhibition as incubation of PD-1 expressing γδ T cells
with PD-L1 expressing tumour cells pre-treated with Zol led to an in-
crease in γδ T cell activation when compared to untreated tumour cells,
suggesting that IPP signalling could overcome PD-L1 inhibition [72].
3.5.2. Treg
T regulatory cells (Tregs) are essential in maintaining peripheral
tolerance by suppressing T effector cell activity. CD4+ Foxp3+ Tregs
are the most widely studied and can be categorised into natural (nTreg),
which are committed cells from the thymus, or induced (iTreg) which
are converted from naïve CD4+ T cells in the periphery, dependent on
TGFβ and IL-2. Tregs express both PD-1 and PD-L1 directly effecting
Treg generation [73,74]; in vivo mouse models demonstrated that the
conversion and maintenance of iTreg was dependent on PD-L1, via
inhibition of the mTOR/AKT pathway [73]. Tregs play an important
role in immunosuppression in the tumour microenvironment, allowing
tumours to evade immune surveillance by suppressing CD4+ CD25-
CD8+ effector T cells. Therefore it is unsurprising that Tregs have been
found to be upregulated in both mouse and human tumours [75] where
Treg infiltration is characteristic of more invasive tumours and predicts
diminished survival.
In mice treated with ZOL, the levels of circulating CD4+, CD8+,
Foxp3+ Tregs were significantly decreased, providing evidence of a
further mechanism of ZOLs immunomodulatory nature [76]. Treg de-
rived RANKL in the tumour microenvironment is central to stimulating
tumour growth, since tumour growth can be stimulated by exogenous
RANKL in the absence of Tregs. The importance of immunomodulation
by Tregs in breast cancer progression has been determined in a series of
in vitro experiments [77]. Treatment with 10 µM ZOL significantly in-
hibited proliferation of Tregs, whilst having no significant effect on
lymphocyte proliferation. The migratory capacity of Tregs in response
to conditioned media from MDA-MB-231 cells was also significantly
inhibited by ZOL suggesting that there would be less tumour infiltration
by Tregs. In addition to the increased migratory capacity of MDA-MB-
231 cells by Tregs, the study also found this migration could be in-
hibited by ZOL through downregulation of RANKL from infiltrating
Treg cells [77]. Further studies confirmed these findings, showing that
treatment of Tregs with ZOL reduced expression of STAT5, TGFβ and
CD25, functionally leading to a reduced capacity of Tregs to supress T
and NK cell proliferation. Analysis of molecular changes in the human
breast cancer cell line MDA-MB-231 following treatment with ZOL re-
vealed a downregulation of CCR4 and CTLA4 [77], both of which have
previously been shown to be vital in the recruitment of Tregs into the
tumour microenvironment [78]. This finding was functionally con-
firmed by a migration assay showing that anti-CCL2 or CCL5 antibodies
significantly inhibited Treg migration in response to MDA-MB-231
conditioned medium [79]. Interestingly, PD-1 expression on Tregs was
significantly downregulated by ZOL, suggesting a reduced capacity for
naïve T cell conversion into mature Tregs, and a loss of CD8+ effector T
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cell expression.
3.5.3. Macrophages
Macrophages, part of the innate immune system, are mononuclear
cells of the myeloid lineage that originate from monocytes in the bone
marrow. Once they leave the bone marrow and enter a tissue, they can
be stimulated to differentiate into macrophages, which can have op-
posing effects on bone metastasis. Macrophages are essential in pro-
moting a specific adaptive immune response by collaborating with T
and B cells to induce or inhibit T cell recruitment and activation [80].
Depending on the cytokines acting on the precursors, macrophages can
differentiate into two broad classes. Firstly, pro-inflammatory anti-tu-
mour macrophages, secreting IL-1, IL-6, IL-12 and IFN-γ to recruit T
cells and eliminate tumour cells [81]. Secondly, tumour associated
macrophages (TAMs) which are considered one of the most important
regulators of tumour progression and bone metastasis [82] since they
secrete cytokines such as IL-10 and TGF-β which decrease CD4+ and
CD8+ T cell activity on the tumour microenvironment [83].
ZOL can alter the polarisation and function of macrophages within
the tumour microenvironment. ZOL has been shown to be taken up by
macrophages both in vivo and in vitro, with 5 µM over 24 h causing
significant increases in unprenylated Rap1A in vitro, a marker for in-
hibition of the mevalonate pathway [84]. Furthermore, macrophages
isolated from breast cancer xenografts also had significantly higher
unprenylated Rap1A following a single dose of Zol [84]. When mice
were treated with ZOL for 3 weeks and their tumours were analysed by
histological methods, it was revealed that ZOL had inhibited TAM in-
filtration and reduced vascularisation, caused by a reverted polarisation
of macrophages away from the TAM polarisation and towards the anti-
tumour polarisation [85].
Interaction between tumour cells and macrophages enhances MMP-
9 expression in TAMs, an enzyme which plays a major role in the in-
vasion and metastasis of breast cancer cells due to its role in ECM re-
modelling [86]. Furthermore, MMP-9 is required by myeloid derived
suppressor cells (MDSC) for their immunosuppressive functions within
the tumour microenvironment. When mice were treated with ZOL, the
levels of MMP-9 and the number of TAMs were significantly decreased,
followed by a reduced expansion of MDSC. This was found to be partly
due to a decrease in bone marrow progenitor derived MMP-9 [87]. A
series of in vitro experiments modelling the cancer cell macrophage
interaction on the presence of ZOL found that ZOL could selectively
supress the expression of MMP-9 in the tumour associated macrophage
population, as well as shifting macrophage polarisation to effectively
drive proliferation of activated γδ T cells [88].
Interestingly, ZOL also affected the interactions of macrophages and
γδ T cells in the tumour microenvironment. Human monocytes were
differentiated into either anti-tumour macrophages or TAMs before
being treated with ZOL in vitro. ZOL treatment rendered the macro-
phages susceptible to γδ T cell cytotoxicity in a perforin dependent
manner, independently of macrophage polarisation [89]. This could go
some way to explaining a mechanism whereby TAMs are cleared from
the tumour microenvironment.
3.5.4. NK cells
Natural Killer (NK) cells are part of the innate immune system and
are also a vital immune cell type having cytotoxic effects on breast
cancer cells by targeting stress induced markers [90]. Research into the
effects of ZOL on NK cell function in breast cancer metastasis is limited,
with conflicting results highlighting the need for further research into
this field. When NK cells and dendritic antigen presenting cells were co-
cultured together in the presence and absence of ZOL, ZOL was shown
to stimulate IFN-γ production in NK cells. This was the result of inter-
actions with dendritic cells where ZOL induced depletion of en-
dogenous prenyl pyrophosphates which lead to the secretion of IL-18
and IL-1β to activate NK cells [91]. Furthermore, this was shown to be
dependent on caspase 1 expression in NK cells. When studying Treg
function in patients with metastatic cancer, ZOL selectively decreased
Treg infiltration. Interestingly, this led to a significant increase in NK
cell proliferation in peripheral blood of patients with metastatic cancer,
possibly mediated via Treg signalling, since ZOL treated Tregs had a
reduced capacity for inhibiting NK cell proliferation [92]. In contrast,
one study investigating the in vitro effects of ZOL on NK cells from
healthy donors and Ewing sarcoma patients found that ZOL sig-
nificantly impaired expansion of NK cells. In this study, ZOL impaired
the degranulation response of NK cells to Ewing sarcoma stimulus
suggesting a decrease in functional activity in which ZOL may help
increase the survival of tumour cells in this context [93].
Overall data show that ZOL has substantial anti-tumour immune
modulatory effects, acting on a plethora of immune cells within the
tumour microenvironment and leading to a general increase in immune
cell infiltrate (Fig. 2). Treg cells, the regulators of T cell immune re-
sponse, are significantly inhibited by ZOL leading to a block in immune
inhibition within the tumour microenvironment and having secondary
consequences by allowing the action of CD8 T cells and NK cells. These
Fig. 2. Effects of ZOL on the immune re-
sponse to breast cancer. ZOL causes a de-
crease in immune suppression within the
tumour microenvironment, mediated
through a decrease in Treg infiltration and
activity, an increase in macrophage polar-
isation towards an anti-tumour phonotype
and an increase in γδ T cell antigen re-
cognition.
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immunomodulatory effects of ZOL could explain why adding this drug
to standard of care following primary tumour resection leads to im-
proved disease-free survival and reduced bone metastasis in post-me-
nopausal women. Why these improved survival effects are not seen in
pre-menopausal women may be due to oestrogen driven alterations in
immune regulation interfering with ZOL driven anti-tumour immune
responses.
3.6. Immune modulatory effects of oestrogen and interactions with ZOL
Oestrogen is immunogenic, influencing the activity and survival of a
plethora of different immune cells expressing the ER, perhaps ex-
plaining the sex-differential response of the immune system to patho-
gens. ER is expressed on dendritic cells, macrophages, mast cells,
neutrophils, NK cells, B cells, CD4+ T cells, CD8+ T cells and Tregs
[92]. Not all these cells have anti-tumour properties, with Tregs, mast
cells and some tumour associated macrophages being linked to a poor
prognosis. Therefore, oestrogen driven immune modulatory effects on
breast cancer metastasis and patient outcome is a complex one. The
contributions of the individual immune cell types to this process is
summarised in the subsections below.
3.6.1. PD-L1
Oestrogen is a strong oncogenic driver in breast cancer, and it has
been shown to modulate immune response. Oestrogen increases PD-L1
protein expression in ER+ve MCF-7 cells via Akt/PI3K activation [94].
This expression was mediated via an increase in mRNA stability since
blocking gene transcription had little effect. When co-cultures with T
cells, oestrogen upregulated PD-L1 in ER+ve breast cancer cells re-
sulting in reduced T cell function, indicated by diminished expression of
IFN-γ and IL-2 suggesting T-cell exhaustion. These effects were in-
dependent of the direct action of oestrogen on T cells [94]. Increased
oestrogen driven expression of PD-L1 may, in part, explain the reduced
sensitivity to the anti-tumour effects of ZOL in pre-menopausal women
as ZOL induces tumour cell killing through increased activation of T
cells and high concentrations of oestrogen may prevent these ZOL ac-
tivated T cells from exerting their anti-tumour activity.
3.6.2. Tregs
Immunosuppressive Treg cells, express ERs which enhance their
function and ability to expand the Treg cell compartment [95] (Fig. 3).
Indeed, pre-menopausal physiological concentrations of oestrogen
given to ovariectomised mice stimulated the conversion of CD4+ CD25-
T cells into CD4+ CD25+ cells while also increasing expression of
Foxp3 and IL-10, which are important Treg cell markers. Furthermore
both in vitro and in vivo studies show that upregulation of Treg cells
leads to enhanced suppression of T cell proliferation and in mixed
lymphocytes. Interestingly, Treg cells have been shown to interact with
the bone resident osteoclasts and modify their bone modulatory func-
tions in vitro, with oestrogen enhancing this effect. Co-cultures of bone
marrow cells and isolated human Tregs in the presence and absence of
oestrogen found that osteoclast differentiation was supressed more ef-
ficiently in the presence of oestrogen, an effect which was mediated via
Treg derived IL-10 and TGF-β1 [96].
Oestrogen induced PD-L1 expression in the metastatic breast cancer
microenvironment augments the immunosuppressive niche by inducing
iTreg conversion. This is particularly important for bone metastasis as
evidenced in a number of studies showing that Tregs are increased in
patients with bone metastasis, with signalling via CXCR4/CXCL12
mediating Treg trafficking to bone suggesting that the bone micro-
environment is a preferential site for functional Tregs [97]. Treg traf-
ficking to bone results in adverse effects for breast cancer patients,
actively promoting metastasis at this site.
Treg cells are a major source of RANKL in the tumour micro-
environment and in the bone, expressing up to four fold more RANKL
than CD4+CD25- T cells [98]. This suggests that Tregs are important for
maintaining RANKL expression in the tumour microenvironment of
metastatic breast cancer. Tregs increased the metastatic potential of
breast cancer cells and exhibited an adverse effect on prognosis. Fur-
thermore, the adverse effects of Tregs was replaceable with addition of
exogenous RANKL [98].
Oestrogen has been shown to regulate Treg cell differentiation and
suppressive activity by inducing PD-1 expression. Intracellular PD-1
expression in Tregs was shown to be oestrogen sensitive and moderated
via the Treg ER. Oestrogen signalling upregulates PD-1 expression,
since ER KO deceased oestrogen mediated PD-1 expression [99]
(Fig. 3). When PD-1 was knocked out of Treg cells, they lost their
functional suppressive activity highlighting the importance of both
oestrogen and the PD-L1/PD-1 axis in immune suppression via Treg
cells [99]. This is in stark contrast to the effects of ZOL on PD-1 ex-
pression. ZOL downregulates PD-1 expression on Tregs, which both
reduces iTreg conversion and reduces the ability of Tregs to function-
ally supress T effector cells in the tumour microenvironment [100].
Furthermore, ZOL was shown to inhibit the proliferation and migratory
capacity of Treg cells which would reduce their capacity to infiltrate the
tumour microenvironment. Oestrogen again does the opposite by
Fig. 3. The effect of oestrogen on the im-
mune response to breast cancer. Oestrogen
increases immune suppression within the
tumour environment, mediated through
increased Treg infiltration and action and
an increased expression of PD-L1.
Furthermore, oestrogen leads to a change in
macrophage polarisation towards a pro-tu-
mourigenic phenotype.
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increasing Treg cell infiltration into tumours via CXCR4/CXCL12 sig-
nalling. It is therefore possible that reduced bone metastasis observed in
both pre- and post-menopausal women treated with adjuvant/neo-ad-
juvant Zol is due to inhibition osteoclastic bone resorption and bone
turnover (as discussed previously). However, under high oestrogen
conditions, increased PD-1/PDL-1 expression may prevent tumour cells
disseminated in other organs from being detected and killed by T cells.
As discussed, Zol has been shown to be a potent activator of T cells
[76–79]. Thus under conditions of low oestrogen, this bisphosphonate
may be able to stimulate an immune response to disseminated tumour
cells reducing metastatic outgrowth in distal organs outside of bone
accounting for the differential effects of adjuvant Zol on soft tissue
metastasis under pre- and post-menopausal conditions (Fig. 4).
3.6.3. T lymphocytes
CD4 and CD8 T lymphocytes are vital in immune protection from
breast cancer metastasis with CD4 assisting B cells in antibody medi-
ated protection and CD8 effector cells important in direct cellular re-
sponses. Studies have shown that increased CD8+ T lymphocytes in the
breast cancer microenvironment correlate with improved overall sur-
vival [101]. CD8+ T cells have also been shown to be a vital defence
against bone metastasis, since escape from T cell detection by MHC
downregulation promotes bone metastasis [102]. However, anti-meta-
static effects associated with bone metastasis are likely to be associated
with early metastatic events as very few CD8+ T cells are detected in
the bone microenvironment [103]. It is therefore likely that alterations
in T cell activity affect tumours in soft tissue more than in bone. Al-
though CD8+ T cells can be silenced in the breast cancer micro-
environment by oestrogen induced Tregs, they also express ERα and are
profoundly influenced by oestrogen signalling (Fig. 3). Furthermore, it
has been known for some time that oestrogen can block early T cell
development in the thymus [104] leading to decreased T cells in mice
following oestrogen administration [105]. This has been shown to be
due to thymic atrophy in the presence of oestrogen, due to decreased
production of Flt3+Sca-1+c-Kit+ thymic homing progenitors and re-
duced proliferation of thymocytes [106].
Oestrogen can also affect CD8+ T cell tumour killing function
within the tumour microenvironment. The main way for cytotoxic
CD8+ T cells to exert their effects is via granule mediated exocytosis of
serine proteases such as granzyme B to initiate caspase mediated
apoptosis in the target tumour cell [107]. Interestingly, when the ER+
breast cancer cell line, MCF-7, was treated with oestrogen it induced
expression of the granzyme B inhibitor PI-9, protecting these cells from
CD8+ T cell targeting, as well as from NK cell mediated apoptosis
[108].
The effect of oestrogen on CD8+ lymphocytes highlights another
overlapping role of oestrogen and ZOL (Fig. 4). In post-menopausal
women, an anti-tumour effect of ZOL can be mediated in part by a
decrease in Treg cell infiltration allowing expansion of CD8+ T cells in
the tumour microenvironment. However, in pre-menopausal women,
CD8+ T cell function in the tumour microenvironment may be further
inhibited by expression of granzyme B inhibitor inhibiting tumour
death. Therefore, even if Treg infiltration is reduced by ZOL, the re-
sulting CD8+ T cell infiltration may still have a diminished function
leading to less tumour killing in soft and increased metastases in these
sites.
3.6.4. Macrophages
Tumour associated macrophages play a vital role in breast cancer
progression and bone metastasis. Indeed, they have been shown to be
involved in a plethora of processes facilitating metastasis: invasion,
vascularisation, intravasation, circulating tumour cell survival, extra-
vasation and pre-metastatic niche formation [109]. Macrophages and
osteoclasts of the bone microenvironment are derived from the same
precursors, suggesting that macrophages may be sensitive to oestrogen
signalling as osteoclasts are. Furthermore, many inflammatory diseases
display a sex difference in their phenotype, which has been suggested to
be via macrophage interactions with oestrogen. In a mouse asthma
model, oestrogen signalling was shown to increase IL4 and M2 mac-
rophage gene expression following OVX and oestrogen administration,
contributing to the gender differences in disease progression [110].
Macrophages express ERα and β, with TAMs expressing ERs across
many cancer types [111]. Oestrogen signalling on macrophage ERs in
the tumour microenvironment can affect macrophage polarisation
(Fig. 3). The mouse polyomavirus middle T ER-positive breast cancer
model was treated with oestrogen, which led to significantly higher M2
macrophage infiltration when compared to untreated controls which
had higher M1 macrophage tumour infiltration [112]. This effect was
found to be mediated via increased expression of CCL2 and CCL5 in
macrophages from the oestrogen treated group [112]. Oestrogen
treated macrophages also expressed and secreted more VEGF, an im-
portant molecule in metastasis progression since it both directly sti-
mulates tumour growth and assists the angiogenic switch in growing
tumours [112]. Furthermore, oestrogen has been reported to upregulate
expression of MMP-9 in macrophages in vitro, an important enzyme
playing a role in extracellular matrix remodelling and tumour invasion
Fig. 4. The overlapping effect of oes-
trogen and ZOL on the immune response
to breast cancer. Oestrogen and ZOL have
overlapping and contrasting effects on the
immune cell subsets and their cytotoxic
effects on breast cancers. These over-
lapping effects could contribute to the
progression of breast cancer metastasis in
pre-menopausal women observed in clin-
ical trials and inform future therapies and
research into these effects.
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[113].
There are several overlapping effects of oestrogen and ZOL on
macrophages (Fig. 4), the first of which being the effect on MMP ex-
pression. Oestrogen has been shown to upregulate MMP-9 expression in
vitro, whereas ZOL decreases expression of MMP-9, thereby reducing
TAM infiltration and tumour invasion and metastasis. These opposing
effects on MMP-9 expression underlines another way that oestrogen
could affect the anti-tumour properties of ZOL [87,113]. Oestrogen
induced increase in MMP-9 could increase the metastatic potential of
breast cancer cells and could explain the discrepancies in pre- and post-
menopausal women as observed in clinical trials. Furthermore, ZOL and
oestrogen have been shown to have opposing effects on macrophage
polarisation with oestrogen upregulating pro-tumour macrophage in-
filtration via increased CCL2 and CCL5 expression and ZOL inhibiting
macrophage tumour infiltration by stimulating polarisation towards an
anti-tumour phenotype.
3.6.5. NK cells
Natural Killer (NK) cells represent another important immune
mediated tumour killing cell present in the bone marrow as part of the
innate immune system. Indeed, when the NK cells are depleted in
cancer models, bone metastasis and uncontrollable proliferation were
observed [102]. NK cells target the tumour by recognising stress in-
duced markers and the downregulation of “self” ligands by binding to
recognisable cancer cell surface ligands, such as the cell stress marker
NKG2D [90]. NK cells target the downregulation of MHC molecules to
identify themselves as self, killing the cells by granule mediated exo-
cytosis and Fas-Fas ligand interactions [114]. However, it has been
shown that a partial loss of HLD class 1 proteins renders the tumours
resistant to both T cell and NK cell attack, suggesting expression level is
vital for NK cell function [115]. Interestingly, ERα and ERβ have both
been described in NK cells, and have significant functional effects on
these cells, with ERβ first being suggested as the main mechanism for
oestrogen response [116]. In mouse models, oestrogen has been shown
to reduce NK cell cytotoxicity in a dose dependent manner in a range of
castrated mouse strains [80,117] (Fig. 3). A clinical study into the ef-
fects of oestrogen replacement on NK cell activity in post-menopausal
women found that oestrogen significantly impaired NK cell activity
when compared to post-menopausal women without oestrogen re-
placement therapy [118]. This suppressive effect of oestrogen on NK
cell activity has been linked to an enhancement of pulmonary metas-
tasis in melanoma and fibrosarcoma. Furthermore, in mouse models of
breast cancer, oestrogen treatment significantly supressed NK cell ac-
tivity and increased tumour size [119]. However, it is unclear whether
this was a direct result of NK cell depletion or the broad effects of
oestrogen. This highlights a contrasting effect of ZOL and oestrogen on
NK cell anti-tumour activity (Fig. 3), however it also highlights the need
for further research into this field. Immunotherapy treatments targeting
NK cells are getting closer to clinical use and ZOL is an important
molecule used in the clinic. Therefore, understanding the interactions
of ZOL and oestrogen on the activity of NK cells is a vital area of re-
search.
3.7. Additional factors to consider
The anti-metastatic effects of adjuvant Zol in post-menopausal
women appear to be limited to breast cancer. No benefits have been
observed in post-menopausal patients with lung cancer or in men fol-
lowing chemical or physical castration with prostate cancer [120].
Furthermore, administration of the anti-RANKL antibody, denosumab,
has similar effects to Zol in that it reduces osteoclastic bone resorption,
increases CD8+ T cells and PDL-1 expression [121]. It has therefore
possible that other, breast cancer specific, factors aside from reduced
circulating concentrations of ovarian hormones may drive or contribute
to response to bisphosphonates in early breast cancer. Analysis of tu-
mour tissue arrays from 1739 patients enrolled on the AZURE trial
(detailed above) has demonstrated direct correlations with expression
of the transcription factor MAF in primary tumours and invasive disease
free survival following administration of Zol [122]. Patents who’s tu-
mours were negative for the expression of MAF demonstrated better
outcome following administration of Zol compared with patients with
MAF expressing primary tumours (HR: 0.52, 95% CI 0.36–0.75) [122]
Interestingly, MAF did not predict patient outcome in the control group
and no correlations between MAF and menopausal status were observed
indicating that this molecule may be an independent prognostic marker
for predicating likely benefit from adjuvant Zol [122]. In addition,
using samples from the same AZURE data sets researchers have iden-
tified other biomarkers that can predict anti-tumour effects of Zol in-
dependently of menopausal status. Patients whose primary tumours
express both macrophage-capping protein (CAPG) and PDZ domain
containing protein (GIPC1) were more likely to develop first distant
recurrence in bone (HR: 4.5, 95% CI, 2.1–9.8; P = 0.01) and had re-
duced overall survival (HR: 1.8, 95% CI, 1.01–3.24; P = 0.45). Zol had
a substantial increased effect in patients with high expression of both
proteins leading to a 10 fold reduction in the hazard ratio for first in-
stance recurrence in bone, compared with control (P = 0.008) [123].
Expression of IL-1B in primary tumours was also shown to correlate
with subsequent relapse in bone (HR: 1.85; 95 CI: 1.05–3.26; P = 0.02)
or other sites (HR: 2.09, CI: 1.26–3.48; P = 0.0016) and expression of
this proinflammatory cytokine was associated with reduced overall
survival in patients treated with zoledronic acid compared with control
(P = 0.002) [124]. Whether alone, or in combination, these potential
biomarkers make better predictors of the potential anti-tumour effects if
Zol compared with menopausal status remains to be established. Fur-
ther research is required to establish potential mechanisms by which
these factors may interact with Zol to influence the metastatic process.
It will also be useful to establish if breast cancers express specific factors
that render them more sensitive to bisphosphonates under post-meno-
pausal conditions or if non-responsiveness to anti-tumour effects of
bisphosphonates observed in lung and prostate cancer are due to other
factors such as differential response to immune regulation.
4. Conclusions
The ability of breast cancer to evade the immune system is vital for
its progression in both primary tumour growth and its ability to me-
tastasise. Oestrogen and ZOL both have profound and often opposing
effects on the immune system and the ability of breast cancer cells to
evade immune detection. Clinical trials have demonstrated that me-
nopausal status affects patient’s response to adjuvant ZOL: Both pre-
and post-menopausal women develop fewer bone metastases following
administration of ZOL suggesting that ZOL is able to exert effects on the
bone microenvironment that make it non-permissive for tumour growth
irrespective of the effects of oestrogen. It has been suggested that under
pre-menopausal concentrations of oestrogen, inhibition of the bone
microenvironment by ZOL, may cause tumour cells to escape to move to
other sites, whereas under post-menopausal concentration of oestrogen,
ZOL either kills tumour cells or holds these in a dormant state within
the bone. These suggestions could in some part explain why pre-me-
nopausal women experience increased soft tissue metastasis following
adjuvant ZOL. This hypothesis remains to be answered and tumour
progression both inside and outside of the bone is tightly regulated by
immune cells suggesting that both bone cell mediated, and immune cell
mediated response to ZOL may play intricate roles in regulating tumour
growth at different sites.
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